TGTXTG Therapeutics, Inc.
Price
+71%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, price roughly fair, growing in the filings, the market undecided.
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
TG Therapeutics, Inc. (TGTX) reported revenue of $240M in Q2 2026 (quarter ended Jun 30, 2026), up 70% from the same quarter a year earlier. That came with a gross margin of 83% and net income of $7.8M (3.2% of revenue). For the full year FY2025, revenue was $616M (+87% year on year) and net income $447M. Its largest product in Q2 2026 was License at $4.5M, 50.0% of the disclosed total, just ahead of License at 50.0%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance.Earnings release · press release
- Jun 3, 2026On June 3, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) in patients with relapsing forms …Other event · Form 8-K
- May 27, 2026On May 27, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $9.1MThe company’s own SEC segment disclosure.
- License$4.5M50%
- License$4.5M50%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.